In 2013 you can meet with SG Austria at:
Meet CEO, Brian Salmons, at the 2013 International Society for Cell Therapy meeting in Auckland, New Zealand, April 22-25, where he will be presenting in the session “Trailblazing in Cell Therapy Clinical Trials”.
Meet Research Scientist, Tan Wee Jin, at the 1st Young Investigators’ Symposium to be held by the Singapore Stem Cell Society at the Biopolis in Singapore on May 31st where he will be presenting on encapsulation of stem cells.
John Dangerfield (COO) and Eliot Read (Project Manager) attended the BioPharma Asia Convention 2013 which was held this year for the first time at Resorts World Sentosa from 18-21st March. A number of new high profile contacts were made with a view to further commercialisation of the Company’s proprietary encapsulation technology.
John Dangerfield (COO) was invited as a Speaker to the BioSpectrum BioScience Forum 2013 in Singapore on March 15 which was part of the BioSpectrum Asia Awards Ceremony at Fort Canning Hotel. The Forum explored the theme “Bioscience VC funding in Asia, a face-off” via interactive panel discussion which lead to an interesting debate being sparked around the subject prior to the awards ceremony. Other SG Austria team members Brian Salmons (CEO), Louise Bussieres (CFO) and Eliot Read (Project Manager) also attended the event.
Austrianova Singapore and it’s partner, the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), have published a new paper on cell encapsulation for the treatment of diabetes. The publication entitled “Cell encapsulation for the treatment of diabetes” appeared in the Wiener Medizinische Wochenschrift Skriptum and discusses encapsulation of cells for treatment of diabetes and, in particular, the advantages of using cellulose sulphate as the encapsulation material of choice. The article accompanied an invited presentation on the same topic at the Austrian Diabetes Meeting in Salzburg, Austria given by Dr. Eva Brandtner, formerly Chief Scientist of Austrianova and now with VIVIT. [click here to view article] (available in German only)
The SG Austria team was at AusBioTech 2012. John Dangerfield (COO), Wee Jin Tan (Research Scientist) and Annie Cunanan (General Admin) attended the AusBiotech event from October 30th to November 2nd which was held at the Melbourne Convention and Exhibition Centre. A steady stream of interest at the booth was complimented by a busy schedule of one-to-one meetings facilitated by the well organised partnering system.
Presented at at the International Society for Cell and Gene Therapy of Cancer at the Furama City Centre Singapore on October 4th – 6th. John Dangerfield, COO, presented a report on a second successful pancreatic clinical trial for the first time. The presentation generated much interest in the technology leading to ongoing discussions with potential partners and customers. A report has been submitted for publication soon in a scientific, peer-reviewed journal. A press release in Asia biggest biomedical community online publication BioSpectrum Asia can be read here [click here for BioSpectrum article]
Attended the World Vaccine Congress 2012, June, Singapore. Topic: COO, Dr John Dangerfield was able to network and generate some interesting business leads at this event which was held at Grand Copthorne Waterfront Hotel in Singapore.
Presented at the Organisation for Oncology and Translation Research (OOTR) Meeting 2012, April, Japan. Topic: Chairman, Prof. Walter H Gunzburg presented Austrianova’s technology for use in cancer therapy relating to the use of stem cells at this event which was held at The Westin Miyako Hotel in Kyoto.
Presented at Cell Line Development and Engineering Asia 2012 Conference, February, China. Topic: CEO, Dr. Brian Salmons presented SG Austria’s own cell line for the treatment of pancreatic cancer at this IBC Asia event which was held at The Grand Hyatt Shanghai, China, in February. The meeting mostly concerned industry developments in the manufacturing of biomedical molecules from eukaryotic cell cultures.
Attended Cell and Gene Therapy Forum 2012 Conference, February, China. Topic: SG Austria’s Senior Business Development Consultant, Dr. Stephen Rhind attended this major event organised by Phacilitate which was held at The Grand Hyatt Washington DC, USA, in January.
Presented at swissnex-SIMTech event, September, Singapore. Topic: Chief Scientist, Dr. Lilli Brandtner presented at the Swiss-Singapore Workshop on Microfluidics which was organised and supported by swissnex and held at A*STAR’s SIMTech institute at Nanyang Technical University in Singapore. The meeting concerned industry developments in the area of microfulidics.
Displayed at BioKorea, September 28-30, COEX, Seoul, Korea. Topic: BioKorea is one of Asia’s most important Biotech events, covering a diverse range of applications and areas such as medical care, food, agriculture, energy, chemical, and the environment.
Sponsored and Presented at: Phacilitate’s Cell and Gene Therapy Forum Asia, September 19-21, Singapore. Topic: COO, Dr John Dangerfield presented in the plenary session “How can the global cell and gene therapy sector address Asia’s most unmet medical needs”. He also chaired and took part in the panel discussion for the focus session on international funding and commercialisation opportunities for Asian cell and gene therapy companies. Dr Stephen Rhind, a consultant to SG Austria, also attended on their behalf.
Displayed at: Bio International Convention 2011, June 27-30, Washington DC, U.S.A. Topic: SG Austria had a attractively designed display booth in the Singapore pavilion along with around 20 other biotech companies from Singapore supported by International Enterprises SG (IE Singapore). The event was a great success with a permanent stream of interested visitors.
Presented at: Cell Therapy Summit Europe 2011, March, Maastrict, Natherlands. Topic: An exclusive gathering of CEOs, investors, academic researchers and other high-level executives examined what it takes to create a successful business and establish a path forward for the mostly uncharted territory of cell therapy.
Invited to: BioSpectrum Asia Pacific Awards 2011, March 16, Singapore. Topic: An afternoon of interest with expert panel members followed by an evening of achievement awards to some of Asia’s best biotech companies.
Presented at: BioEurope 2010, Munich, Germany, 15-17 November. Session: The Perfect Pitch.
Presented at: Stem Cell Society, Singapore Symposium 2010, Singapore, 3 November. Topic: Cell in a Box technology: biomedical applications and clinical experience.
Presented at: CliniGene Industry satellite of the XVIII Annual Congress of the European Society of Gene and Cell Therapy, Milan, Italy, 25 October. Topic: Models for Industry development: Financing the development of gene and genetically modified cell therapies
Presented at XVIII Annual Congress of the European Society of Gene and Cell Therapy. Milan, Italy, 22 – 25 October
Presented at: Pharma Licensing Strategies Asia 2010, Singapore, 15 September 2010. Topics: ‘Cell Encapsulation Technology allowing cells to be implanted for long term therapy’ and ‘Post-Exit Surface Modification of Enveloped Viruses And Viral Vectors’.
Presented at: International Conference on Cellular & Molecular Bioengineering (ICCMB2), NTU, Singapore, 02 August. Topic: Past clinical success and new developments with live cell encapsulation for the treatment of cancer and other serious diseases
Presented at: 1st NUHS-KCL Gene Therapy, NUS, Singapore 05 March. Topic: Gene and cell therapies for cancer- different strategies and clinical experiences.